Oxford BioMedica plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oxford BioMedica plc
Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.
Scrip takes an infographic look at where South Korea stands in the development of a wide-ranging set of drugs for Alzheimer’s disease and which companies are still in the challenging race.
PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Oxxon Therapeutics Limited